Figure 5.

Pinocembrin increases glycolysis in primary cardiomyocytes. (a) Glycolysis stress test in rat cardiomyocytes measured as the ECAR by sequential injection of 20 mM glucose, 1 μM oligomycin followed by 100 mM 2-deoxy-d-glucose (2-DG). (b) Quantitative analysis of glycolysis, glycolytic capacity, and glycolytic reserves in rat cardiomyocytes. (c) Glycolysis stress test in mouse cardiomyocytes measured as the ECAR by sequential injection of 20 mM glucose, 1 μM oligomycin, and 100 mM 2-DG. (d) Quantitative analysis of glycolysis, glycolytic capacity, and glycolytic reserves in mouse cardiomyocytes pretreated with pinocembrin or control. (e) Mouse cardiomyocytes were treated with pinocembrin for 24 h, and then, the glycolysis-related genes were detected by qRT-PCR. n = 3/treatment in all Seahorse assays, each in triplicate. Data represent the mean ± SEM. ^∗P < 0.05 indicates a significant difference. NS indicates no significant difference